4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-16-000087
$BHCCIK 0000885590operating
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 5:39 PM ET
Size
7.8 KB
Accession
0000885590-16-000087
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Tax Payment
Common Stock, no par value
2016-02-18$91.45/sh−2,245$205,305→ 388,630 total - Tax Payment
Common Stock, no par value
2016-02-18$91.45/sh−51,846$4,741,317→ 336,784 total
Footnotes (4)
- [F1]Represents the amount of shares withheld by the registrant to cover certain tax obligations due upon vesting of Matching Restricted Share Units.
- [F2]This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II, giving effect to the cancellation of such PSUs in respect of a potential 200,000 Common Shares. See note (3).
- [F3]The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $136.41 starting on December 1, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% would vest on September 1, 2017, 50% on December 1, 2017 and 25% on March 1, 2018, (or 25% on September 1, 2018, 50% on December 1, 2018 and 25% on March 1, 2019, if applicable). Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels.
- [F4]Represents the amount of shares withheld to cover certain tax obligations due upon vesting of Performance Restricted Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 5:39 PM ET
- Size
- 7.8 KB